Work

Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.698

Authors: Praful Ravi, Ziad Bakouny, Ronan Flippot, David A. Braun, Sarah Abou Alaiwi, Xiao X. Wei, Bradley Alexander McGregor, Kerry L. Kilbridge, Atish Dipankar Choudhury, Lauren Christine Harshman, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, Pitié-Salpêtrière Hospital, Stanford Medicine, Stanford University, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3008367446

Cites:

Cited by:

Related to: 10